<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Homocystinurie - Lerneinheit</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary-color: #667eea;
            --secondary-color: #764ba2;
            --accent-color: #f093fb;
            --success-color: #4facfe;
            --warning-color: #fa709a;
            --danger-color: #ff6b6b;
            --info-color: #74b9ff;
            --text-primary: #2d3748;
            --text-secondary: #4a5568;
            --text-muted: #718096;
            --bg-white: #ffffff;
            --bg-light: #f8fafc;
            --bg-lighter: #f1f5f9;
            --border-radius: 16px;
            --border-radius-lg: 24px;
            --spacing-xs: 8px;
            --spacing-sm: 16px;
            --spacing-md: 24px;
            --spacing-lg: 32px;
            --spacing-xl: 48px;
            --shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            --shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
            --shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }
        
        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            min-height: 100vh;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: var(--spacing-md);
        }
        
        /* Header */
        .header {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
        }
        
        .header h1 {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
            background-size: 200% 200%;
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: clamp(2rem, 5vw, 3.5rem);
            font-weight: 700;
            margin-bottom: var(--spacing-sm);
            animation: gradientShift 4s ease-in-out infinite;
        }
        
        @keyframes gradientShift {
            0%, 100% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
        }
        
        .header p {
            color: var(--text-secondary);
            font-size: 1.3rem;
            font-weight: 400;
        }
        
        /* Progress bar */
        .progress-container {
            background: var(--bg-lighter);
            border-radius: 50px;
            height: 10px;
            margin-top: var(--spacing-md);
            overflow: hidden;
        }
        
        .progress-fill {
            background: linear-gradient(90deg, var(--success-color), #00f2fe);
            height: 100%;
            border-radius: 50px;
            transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
            position: relative;
            overflow: hidden;
        }
        
        .progress-fill::after {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
            animation: progressShimmer 2s infinite;
        }
        
        @keyframes progressShimmer {
            0% { transform: translateX(-100%); }
            100% { transform: translateX(100%); }
        }
        
        /* Navigation */
        .navigation {
            background: var(--bg-white);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            display: flex;
            flex-wrap: wrap;
            gap: var(--spacing-sm);
            justify-content: center;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .nav-btn {
            background: var(--bg-light);
            border: 2px solid #e2e8f0;
            color: var(--text-primary);
            padding: 16px 24px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 14px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .nav-btn:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
            border-color: var(--primary-color);
        }
        
        .nav-btn.active {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }
        
        /* Content sections */
        .content-section {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
            display: none;
        }
        
        .content-section.active {
            display: block;
            animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
        }
        
        @keyframes slideInUp {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .section-title {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: var(--spacing-lg);
            position: relative;
            padding-bottom: var(--spacing-sm);
        }
        
        .section-title::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 4px;
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            border-radius: 2px;
            animation: expandWidth 0.8s ease-out 0.3s both;
        }
        
        @keyframes expandWidth {
            from { width: 0; }
            to { width: 60px; }
        }
        
        /* Subsections */
        .subsection {
            margin-bottom: var(--spacing-lg);
            padding: var(--spacing-lg);
            background: var(--bg-light);
            border-radius: var(--border-radius);
            border: 1px solid #e2e8f0;
            transition: all 0.3s ease;
        }
        
        .subsection:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
        }
        
        .subsection h3 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.5rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .subsection h3::before {
            content: '';
            width: 4px;
            height: 24px;
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            border-radius: 2px;
        }
        
        .subsection p {
            color: var(--text-secondary);
            margin-bottom: 1rem;
            line-height: 1.7;
        }
        
        .subsection ul {
            color: var(--text-secondary);
            padding-left: 1.5rem;
        }
        
        .subsection li {
            margin-bottom: 0.5rem;
        }
        
        /* Tables */
        .clinical-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: var(--spacing-md) 0;
            background: var(--bg-white);
            border-radius: var(--border-radius);
            overflow: hidden;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .clinical-table th {
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            color: white;
            padding: var(--spacing-md);
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .clinical-table td {
            padding: var(--spacing-md);
            border-bottom: 1px solid #f1f5f9;
            transition: all 0.3s ease;
            color: var(--text-primary);
        }
        
        .clinical-table tbody tr:hover {
            background: #f8fafc;
        }
        
        .clinical-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Pathway diagrams */
        .pathway-diagram {
            background: var(--bg-white);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .pathway-diagram h4 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            text-align: center;
        }
        
        .pathway-diagram h5 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-sm);
            font-weight: 600;
        }
        
        .pathway-diagram p {
            color: var(--text-secondary);
        }
        
        /* Enzyme boxes */
        .enzyme-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--info-color), var(--primary-color));
            color: white;
            padding: 12px 20px;
            margin: 6px;
            border-radius: 12px;
            font-weight: 600;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .enzyme-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        .enzyme-box.defect {
            background: linear-gradient(135deg, var(--danger-color), #ee5a24);
            animation: pulseGlow 2s infinite;
        }
        
        @keyframes pulseGlow {
            0%, 100% {
                transform: scale(1);
                box-shadow: var(--shadow-sm);
            }
            50% {
                transform: scale(1.02);
                box-shadow: var(--shadow-md);
            }
        }
        
        .arrow {
            display: inline-block;
            margin: 0 var(--spacing-sm);
            font-size: 1.8rem;
            color: var(--primary-color);
            transition: all 0.3s ease;
        }
        
        .arrow:hover {
            transform: scale(1.2);
            color: var(--accent-color);
        }
        
        /* Highlight boxes */
        .highlight-box {
            background: linear-gradient(135deg, #fff7ed, #fed7aa);
            border: 2px solid var(--warning-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            position: relative;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box::before {
            content: '‚ö†Ô∏è';
            position: absolute;
            top: -12px;
            left: 24px;
            background: linear-gradient(135deg, var(--warning-color), #fee140);
            padding: 8px 12px;
            border-radius: 50%;
            font-size: 1.2rem;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box h4 {
            color: #92400e;
            margin-bottom: var(--spacing-sm);
            margin-top: var(--spacing-sm);
            font-weight: 600;
        }
        
        .highlight-box p, .highlight-box ul, .highlight-box li {
            color: #92400e;
        }
        
        /* Case study boxes */
        .case-study {
            background: linear-gradient(135deg, #f0fdf4, #dcfce7);
            border: 2px solid var(--success-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .case-study h4 {
            color: #166534;
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .case-study p, .case-study ul, .case-study li {
            color: #166534;
        }
        
        /* Metabolite boxes */
        .metabolite-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--warning-color), #fee140);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .metabolite-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        /* Buttons */
        .next-step {
            text-align: center;
            margin-top: var(--spacing-xl);
        }
        
        .next-btn {
            background: linear-gradient(135deg, var(--success-color), #00f2fe);
            color: white;
            border: none;
            padding: 18px 36px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 16px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            box-shadow: var(--shadow-md);
            text-transform: uppercase;
            letter-spacing: 1px;
        }
        
        .next-btn:hover {
            transform: translateY(-4px) scale(1.05);
            box-shadow: var(--shadow-lg);
        }
        
        /* Diagnostic flow */
        .diagnostic-flow {
            display: flex;
            flex-direction: column;
            align-items: center;
            gap: var(--spacing-md);
            margin: var(--spacing-md) 0;
        }
        
        .flow-step {
            background: var(--bg-white);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            max-width: 320px;
            text-align: center;
            transition: all 0.3s ease;
            color: var(--text-primary);
            box-shadow: var(--shadow-sm);
        }
        
        .flow-step:hover {
            transform: translateY(-4px) scale(1.02);
            box-shadow: var(--shadow-md);
        }
        
        .flow-arrow {
            width: 0;
            height: 0;
            border-left: 12px solid transparent;
            border-right: 12px solid transparent;
            border-top: 20px solid var(--info-color);
            animation: bounce 2s infinite;
        }
        
        @keyframes bounce {
            0%, 100% { transform: translateY(0); }
            50% { transform: translateY(-5px); }
        }
        
        .part-info {
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-sm);
        }
        
        .part-info h3 {
            color: var(--info-color);
            margin-bottom: var(--spacing-sm);
        }
        
        .part-info p {
            color: var(--text-secondary);
        }
        
        /* Responsive design */
        @media (max-width: 768px) {
            .container {
                padding: var(--spacing-sm);
            }
            
            .header h1 {
                font-size: 2.5rem;
            }
            
            .header p {
                font-size: 1.1rem;
            }
            
            .navigation {
                flex-direction: column;
            }
            
            .nav-btn {
                width: 100%;
                text-align: center;
            }
            
            .content-section {
                padding: var(--spacing-md);
            }
            
            .section-title {
                font-size: 2rem;
            }
            
            .subsection {
                padding: var(--spacing-md);
            }
        }
        
        @media (max-width: 480px) {
            .header {
                padding: var(--spacing-md);
            }
            
            .header h1 {
                font-size: 2rem;
            }
            
            .section-title {
                font-size: 1.8rem;
            }
        }
        
        /* Animation stagger */
        .subsection {
            animation: fadeInStagger 0.6s ease-out both;
        }
        
        @keyframes fadeInStagger {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .subsection:nth-child(1) { animation-delay: 0.1s; }
        .subsection:nth-child(2) { animation-delay: 0.2s; }
        .subsection:nth-child(3) { animation-delay: 0.3s; }
        .subsection:nth-child(4) { animation-delay: 0.4s; }
        .subsection:nth-child(5) { animation-delay: 0.5s; }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>üß¨ Homocystinurie</h1>
            <p>Angeborene St√∂rungen des Methionin-Stoffwechsels</p>
            <div class="progress-container">
                <div class="progress-fill" id="progressBar" style="width: 0%"></div>
            </div>
        </div>

        <div class="part-info">
            <h3>üìö Expertenwissen Homocystinurie</h3>
            <p>Umfassende Lerneinheit zu angeborenen Defekten des Methionin-Zyklus f√ºr Stoffwechselspezialisten</p>
        </div>

        <div class="navigation">
            <button class="nav-btn active" onclick="showSection('grundlagen')">1. Grundlagen</button>
            <button class="nav-btn" onclick="showSection('biochemie')">2. Biochemie</button>
            <button class="nav-btn" onclick="showSection('klinik')">3. Klinisches Bild</button>
            <button class="nav-btn" onclick="showSection('diagnostik')">4. Diagnostik</button>
        </div>

        <!-- Grundlagen -->
        <div class="content-section active" id="grundlagen">
            <h2 class="section-title">üéØ Grundlagen der Homocystinurie</h2>
            
            <div class="subsection">
                <h3>Definition und Klassifikation</h3>
                <p>Homocystinurie umfasst eine heterogene Gruppe angeborener Stoffwechseldefekte, die zu erh√∂hten Homocystein- oder Homocystin-Spiegeln im Plasma und Urin f√ºhren. Die Erkrankungen betreffen verschiedene Enzyme und Cofaktoren des Methionin-Zyklus und der Transsulfurierung.</p>
                
                <div class="highlight-box">
                    <h4>Hauptformen der Homocystinurie</h4>
                    <ul>
                        <li><strong>CBS-Mangel</strong> - Cystathionin-Œ≤-Synthase-Defekt (h√§ufigste Form)</li>
                        <li><strong>Remethylierungsdefekte</strong> - MTHFR, MTR, MTRR, MMADHC</li>
                        <li><strong>Cofaktorm√§ngel</strong> - Fols√§ure-, Cobalamin-abh√§ngige Formen</li>
                        <li><strong>Sekund√§re Formen</strong> - Medikament√∂s, nutritiv, renal</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Epidemiologie</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Form</th>
                            <th>Inzidenz</th>
                            <th>Vererbung</th>
                            <th>Hauptgen</th>
                            <th>Besonderheiten</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>CBS-Mangel</strong></td>
                            <td>1:200.000 - 1:335.000</td>
                            <td>autosomal-rezessiv</td>
                            <td>CBS</td>
                            <td>H√∂here Pr√§valenz in Irland</td>
                        </tr>
                        <tr>
                            <td><strong>MTHFR-Mangel</strong></td>
                            <td>1:200.000</td>
                            <td>autosomal-rezessiv</td>
                            <td>MTHFR</td>
                            <td>Schwere Thermolabilit√§t</td>
                        </tr>
                        <tr>
                            <td><strong>CblC-Defekt</strong></td>
                            <td>1:100.000</td>
                            <td>autosomal-rezessiv</td>
                            <td>MMACHC</td>
                            <td>H√§ufigster Cbl-Defekt</td>
                        </tr>
                        <tr>
                            <td><strong>CblG-Defekt</strong></td>
                            <td>1:500.000</td>
                            <td>autosomal-rezessiv</td>
                            <td>MTR</td>
                            <td>Methionin-Synthase-Defekt</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Historischer Hintergrund</h3>
                <div class="case-study">
                    <h4>üèõÔ∏è Meilensteine der Homocystinurie-Forschung</h4>
                    <p><strong>1962:</strong> Carson und Neill - Erstbeschreibung der Homocystinurie</p>
                    <p><strong>1964:</strong> Gerritsen - Identifikation als CBS-Mangel</p>
                    <p><strong>1970er:</strong> Entdeckung der B6-responsiven Formen</p>
                    <p><strong>1985:</strong> Erste Beschreibung der Remethylierungsdefekte</p>
                    <p><strong>1990er:</strong> Molekulargenetische Charakterisierung</p>
                    <p><strong>2000er:</strong> Etablierung des Neugeborenenscreenings (MS/MS)</p>
                </div>
            </div>

            <div class="subsection">
                <h3>Pathophysiologische Grundprinzipien</h3>
                <div class="pathway-diagram">
                    <h4>Zwei Hauptmechanismen der Krankheitsentstehung</h4>
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 12px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 15px;">‚ö° Toxische Akkumulation</h5>
                            <p style="color: #dc2626;">Homocystein/Homocystin-Anstau</p>
                            <div class="arrow" style="color: #dc2626;">‚Üì</div>
                            <p style="color: #dc2626;">Endothelsch√§digung, Thrombosen</p>
                        </div>
                        <div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fff7ed, #fed7aa); border-radius: 12px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 15px;">‚ò¢Ô∏è Substratmangel</h5>
                            <p style="color: #ea580c;">Cystin/Methionin-Defizit</p>
                            <div class="arrow" style="color: #ea580c;">‚Üì</div>
                            <p style="color: #ea580c;">Bindegewebsschw√§che, ZNS-St√∂rungen</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Klinische Spektren nach Defekttyp</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Defekttyp</th>
                            <th>Homocystein</th>
                            <th>Methionin</th>
                            <th>Hauptsymptome</th>
                            <th>Therapieansatz</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>CBS-Mangel</strong></td>
                            <td>‚Üë‚Üë‚Üë (>100 Œºmol/l)</td>
                            <td>‚Üë‚Üë (>400 Œºmol/l)</td>
                            <td>Marfanoid, Linsenektopie, MR</td>
                            <td>B6, Met-Restriktion, Betain</td>
                        </tr>
                        <tr>
                            <td><strong>MTHFR-Mangel</strong></td>
                            <td>‚Üë‚Üë (50-100 Œºmol/l)</td>
                            <td>‚Üì (<15 Œºmol/l)</td>
                            <td>Mikrozephalie, Krampfanf√§lle</td>
                            <td>Fols√§ure, Betain</td>
                        </tr>
                        <tr>
                            <td><strong>CblC-Defekt</strong></td>
                            <td>‚Üë‚Üë (40-200 Œºmol/l)</td>
                            <td>‚Üì (<15 Œºmol/l)</td>
                            <td>Megaloblast√§re An√§mie, Retinopathie</td>
                            <td>OH-Cbl, Betain</td>
                        </tr>
                        <tr>
                            <td><strong>CblG-Defekt</strong></td>
                            <td>‚Üë (30-80 Œºmol/l)</td>
                            <td>‚Üì (<10 Œºmol/l)</td>
                            <td>Megaloblast√§re An√§mie, ZNS</td>
                            <td>Me-Cbl, Betain</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('biochemie')">Weiter zur Biochemie ‚Üí</button>
            </div>
        </div>

        <!-- Biochemie -->
        <div class="content-section" id="biochemie">
            <h2 class="section-title">‚öóÔ∏è Biochemische Grundlagen</h2>
            
            <div class="subsection">
                <h3>Der Methionin-Zyklus im Detail</h3>
                <div class="pathway-diagram">
                    <h4>Zentraler Stoffwechselweg: Ein-Kohlenstoff-Metabolismus</h4>
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">Methionin</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">MAT</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">S-Adenosylmethionin (SAM)</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 1: Aktivierung zu universeller Methylgruppen-Donator</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">SAM</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Methyltransferasen</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">S-Adenosylhomocystein (SAH)</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 2: Methylierung von DNA, Proteinen, Neurotransmittern</div>
                        
                        <div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
                            <div class="enzyme-box">SAH</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">SAHH</div>
                            <span class="arrow">‚Üí</span>
                            <div class="enzyme-box">Homocystein</div>
                        </div>
                        <div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 3: Irreversible Hydrolyse zu Homocystein</div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <h4>Kritische Punkte des Methionin-Zyklus</h4>
                    <ul>
                        <li><strong>SAM/SAH-Ratio:</strong> Entscheidend f√ºr Methylierungskapazit√§t</li>
                        <li><strong>SAHH-Reaktion:</strong> Thermodynamisch ung√ºnstig, ben√∂tigt Homocystein-Clearance</li>
                        <li><strong>Homocystein-Knotenpunkt:</strong> Remethylierung vs. Transsulfurierung</li>
                        <li><strong>Redox-Balance:</strong> Homocystein ‚áå Homocystin-Gleichgewicht</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Homocystein-Metabolismus: Zwei Entsorgungswege</h3>
                <div class="pathway-diagram">
                    <h4>Remethylierung vs. Transsulfurierung</h4>
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div style="background: #f0fdf4; padding: 15px; border-radius: 8px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 10px;">üîÑ Remethylierung (Recycling)</h5>
                            <div style="text-align: center; margin: 10px 0;">
                                <div class="enzyme-box" style="background: linear-gradient(135deg, #16a34a, #15803d); margin: 5px auto;">Homocystein</div>
                                <div class="arrow" style="color: #16a34a;">‚Üì</div>
                                <div class="enzyme-box" style="background: linear-gradient(135deg, #16a34a, #15803d); margin: 5px auto;">MTHFR/MTR</div>
                                <div class="arrow" style="color: #16a34a;">‚Üì</div>
                                <div class="enzyme-box" style="background: linear-gradient(135deg, #16a34a, #15803d); margin: 5px auto;">Methionin</div>
                            </div>
                            <p style="color: #16a34a; font-size: 0.9em; text-align: center;"><strong>Cofaktoren:</strong> Folat, B12</p>
                        </div>
                        
                        <div style="background: #eff6ff; padding: 15px; border-radius: 8px; border: 2px solid #3b82f6;">
                            <h5 style="color: #2563eb; margin-bottom: 10px;">üö™ Transsulfurierung (Abbau)</h5>
                            <div style="text-align: center; margin: 10px 0;">
                                <div class="enzyme-box" style="background: linear-gradient(135deg, #2563eb, #1d4ed8); margin: 5px auto;">Homocystein</div>
                                <div class="arrow" style="color: #2563eb;">‚Üì</div>
                                <div class="enzyme-box defect" style="margin: 5px auto;">CBS</div>
                                <div class="arrow" style="color: #2563eb;">‚Üì</div>
                                <div class="enzyme-box" style="background: linear-gradient(135deg, #2563eb, #1d4ed8); margin: 5px auto;">Cystin</div>
                            </div>
                            <p style="color: #2563eb; font-size: 0.9em; text-align: center;"><strong>Cofaktoren:</strong> B6 (PLP)</p>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>CBS-Mangel: Molekulare Pathophysiologie</h3>
                <div class="case-study">
                    <h4>üî¨ Cystathionin-Œ≤-Synthase im Detail</h4>
                    <p><strong>Enzym-Eigenschaften:</strong></p>
                    <ul>
                        <li><strong>Lokalisation:</strong> Cytosol, besonders Leber, Niere, Gehirn</li>
                        <li><strong>Cofaktor:</strong> Pyridoxal-5'-Phosphat (PLP/Vitamin B6)</li>
                        <li><strong>Reaktion:</strong> Homocystein + Serin ‚Üí Cystathionin + H‚ÇÇO</li>
                        <li><strong>Regulation:</strong> Allosterisch durch S-Adenosylmethionin</li>
                    </ul>
                    
                    <p><strong>B6-Responsivit√§t:</strong></p>
                    <ul>
                        <li><strong>Responsive Formen (~50%):</strong> Partielle Aktivit√§t, bessere Prognose</li>
                        <li><strong>Non-responsive Formen:</strong> Schwere Mutationen, kompletter Aktivit√§tsverlust</li>
                        <li><strong>Testdosis:</strong> 100-500 mg B6/Tag √ºber 6 Wochen</li>
                        <li><strong>Response-Kriterium:</strong> >20% Homocystein-Reduktion</li>
                    </ul>
                </div>
                
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Mutation-Typ</th>
                            <th>Residuale Aktivit√§t</th>
                            <th>B6-Response</th>
                            <th>Klinischer Ph√§notyp</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Null-Mutationen</strong></td>
                            <td>0-5%</td>
                            <td>Nein</td>
                            <td>Schwer, fr√ºhe Manifestation</td>
                        </tr>
                        <tr>
                            <td><strong>Missense (schwer)</strong></td>
                            <td>5-15%</td>
                            <td>Selten</td>
                            <td>Schwer bis moderat</td>
                        </tr>
                        <tr>
                            <td><strong>Missense (mild)</strong></td>
                            <td>15-30%</td>
                            <td>H√§ufig</td>
                            <td>Moderat, sp√§ter Beginn</td>
                        </tr>
                        <tr>
                            <td><strong>Splice-Varianten</strong></td>
                            <td>Variable</td>
                            <td>M√∂glich</td>
                            <td>Sehr variabel</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Remethylierungsdefekte: Folat- und B12-Stoffwechsel</h3>
                <div class="pathway-diagram">
                    <h4>Ein-Kohlenstoff-Folat-Zyklus</h4>
                    <div style="background: linear-gradient(90deg, #f3f4f6 50%, #e5e7eb 50%); padding: 20px; border-radius: 10px; margin: 20px 0;">
                        <div style="text-align: center; margin-bottom: 15px;">
                            <span style="margin-right: 50px; font-weight: bold;">Folat-Zyklus</span>
                            <span style="font-weight: bold;">Methionin-Synthase</span>
                        </div>
                        
                        <div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #ea580c, #dc2626);">5,10-MTHF</div>
                            <span class="arrow" style="margin: 0 10px;">MTHFR‚Üí</span>
                            <div class="enzyme-box defect">5-MTHF</div>
                        </div>
                        
                        <div style="text-align: center; margin: 15px 0; font-size: 1.2em;">
                            ‚¨áÔ∏è <strong>B12-abh√§ngige Remethylierung</strong> ‚¨áÔ∏è
                        </div>
                        
                        <div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9);">5-MTHF + Hcy</div>
                            <span class="arrow" style="margin: 0 10px;">MTR+B12‚Üí</span>
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #16a34a, #15803d);">THF + Methionin</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <h4>Cobalamin-Cofaktor-Defekte (Cbl-Defekte)</h4>
                    <p><strong>Biochemische Klassifikation:</strong></p>
                    <ul>
                        <li><strong>CblA, CblB:</strong> Adenosylcobalamin-Synthese ‚Üí Methylmalons√§ure ‚Üë</li>
                        <li><strong>CblC, CblD:</strong> Beide Cbl-Formen ‚Üí MMA ‚Üë + Homocystein ‚Üë</li>
                        <li><strong>CblE, CblG:</strong> Methylcobalamin-Synthese ‚Üí nur Homocystein ‚Üë</li>
                        <li><strong>CblF:</strong> Lysosomaler Cbl-Export ‚Üí kombinierter Defekt</li>
                    </ul>
                    
                    <p><strong>CblC-Defekt (h√§ufigster):</strong></p>
                    <ul>
                        <li><strong>Fr√ºhe Form:</strong> Pr√§nataler Beginn, schwere Retinopathie</li>
                        <li><strong>Sp√§te Form:</strong> Jugend/Erwachsenenalter, ZNS-Symptome</li>
                        <li><strong>Therapie:</strong> Hydroxocobalamin + Betain + Fols√§ure</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Biochemische Folgen der Homocystein-Akkumulation</h3>
                <div class="pathway-diagram">
                    <h4>Toxische Mechanismen im Detail</h4>
                    <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 20px 0;">
                        <div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 10px;">üíî Vaskul√§re Toxizit√§t</h5>
                            <ul style="font-size: 0.9em; color: #dc2626;">
                                <li>Endothel-Dysfunktion</li>
                                <li>NO-Inaktivierung</li>
                                <li>Oxidativer Stress</li>
                                <li>Thrombose-Neigung ‚Üë</li>
                            </ul>
                        </div>
                        
                        <div style="background: linear-gradient(135deg, #fff7ed, #fed7aa); padding: 15px; border-radius: 8px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 10px;">üß† Neurotoxizit√§t</h5>
                            <ul style="font-size: 0.9em; color: #ea580c;">
                                <li>NMDA-Rezeptor-Aktivierung</li>
                                <li>Exzitotoxizit√§t</li>
                                <li>Myelinisierungs-St√∂rungen</li>
                                <li>DNA-Hypomethylierung</li>
                            </ul>
                        </div>
                        
                        <div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 15px; border-radius: 8px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 10px;">üîó Kollagen-Defekte</h5>
                            <ul style="font-size: 0.9em; color: #16a34a;">
                                <li>Cross-linking gest√∂rt</li>
                                <li>Bindegewebsschw√§che</li>
                                <li>Linsen-Zonula-Defekte</li>
                                <li>Skelett-Anomalien</li>
                            </ul>
                        </div>
                        
                        <div style="background: linear-gradient(135deg, #eff6ff, #dbeafe); padding: 15px; border-radius: 8px; border: 2px solid #3b82f6;">
                            <h5 style="color: #2563eb; margin-bottom: 10px;">‚öñÔ∏è Methylierungs-St√∂rung</h5>
                            <ul style="font-size: 0.9em; color: #2563eb;">
                                <li>SAM/SAH-Imbalance</li>
                                <li>DNA-Methylierung ‚Üì</li>
                                <li>Neurotransmitter-Synthese ‚Üì</li>
                                <li>Epigenetische Dysregulation</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Labordiagnostische Biomarker</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Analyt</th>
                            <th>Normbereich</th>
                            <th>CBS-Mangel</th>
                            <th>Remethylierungs-Defekt</th>
                            <th>Interpretation</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Total Homocystein</strong></td>
                            <td>5-15 Œºmol/l</td>
                            <td>100-500 Œºmol/l</td>
                            <td>30-200 Œºmol/l</td>
                            <td>Hauptmarker, Therapiemonitoring</td>
                        </tr>
                        <tr>
                            <td><strong>Methionin</strong></td>
                            <td>15-40 Œºmol/l</td>
                            <td>200-2000 Œºmol/l</td>
                            <td>5-15 Œºmol/l</td>
                            <td>Differentialdiagnose</td>
                        </tr>
                        <tr>
                            <td><strong>Cystathionin</strong></td>
                            <td><10 Œºmol/l</td>
                            <td>‚Üì‚Üì oder n.n.</td>
                            <td>Normal</td>
                            <td>CBS-Aktivit√§tsmarker</td>
                        </tr>
                        <tr>
                            <td><strong>Methylmalons√§ure</strong></td>
                            <td><0,3 Œºmol/mmol Krea</td>
                            <td>Normal</td>
                            <td>‚Üë‚Üë (CblC, CblF)</td>
                            <td>Cbl-Stoffwechsel</td>
                        </tr>
                        <tr>
                            <td><strong>SAM/SAH-Ratio</strong></td>
                            <td>>2,5</td>
                            <td><1,5</td>
                            <td><1,0</td>
                            <td>Methylierungs-Status</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('klinik')">Weiter zum klinischen Bild ‚Üí</button>
            </div>
        </div>

        <!-- Klinisches Bild -->
        <div class="content-section" id="klinik">
            <h2 class="section-title">üè• Klinisches Bild</h2>
            
            <div class="subsection">
                <h3>CBS-Mangel: Klassische Homocystinurie</h3>
                <div class="case-study">
                    <h4>üìã Typische Manifestationen nach Organsystem</h4>
                    <p><strong>Ophthalmologisch (90% der Patienten):</strong></p>
                    <ul>
                        <li><strong>Linsenektopie:</strong> Nach unten-innen (vs. Marfan: oben-au√üen)</li>
                        <li><strong>Myopie:</strong> H√§ufig hochgradig (-10 bis -20 dpt)</li>
                        <li><strong>Iridodonesis:</strong> Schlottern der Iris bei Pupillenbewegung</li>
                        <li><strong>Glaukom:</strong> Sekund√§r durch Linsenluxation</li>
                        <li><strong>Retinale Abl√∂sung:</strong> Bei schwerem Myopie</li>
                    </ul>
                    
                    <p><strong>Skelettale Anomalien (80-90%):</strong></p>
                    <ul>
                        <li><strong>Marfanoider Habitus:</strong> Hochwuchs, Arachnodaktylie</li>
                        <li><strong>Wirbels√§ule:</strong> Skoliose, Pectus-Deformit√§t</li>
                        <li><strong>Osteoporose:</strong> Fr√ºhzeitig, erh√∂hte Frakturneigung</li>
                        <li><strong>Arthropathie:</strong> Gelenksteifigkeit, Kontrakturen</li>
                        <li><strong>Genu valgum:</strong> X-Bein-Deformit√§t h√§ufig</li>
                    </ul>
                </div>
                
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Organsystem</th>
                            <th>H√§ufigkeit</th>
                            <th>Hauptmanifestationen</th>
                            <th>Altersabh√§ngigkeit</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Augen</strong></td>
                            <td>90-95%</td>
                            <td>Linsenektopie, Myopie, Glaukom</td>
                            <td>Meist vor 10. Lebensjahr</td>
                        </tr>
                        <tr>
                            <td><strong>Skelett</strong></td>
                            <td>80-90%</td>
                            <td>Marfanoider Habitus, Osteoporose</td>
                            <td>Progressiv ab Kleinkindalter</td>
                        </tr>
                        <tr>
                            <td><strong>ZNS</strong></td>
                            <td>50-65%</td>
                            <td>Intelligenzminderung, Krampfanf√§lle</td>
                            <td>Fr√ºhe Diagnose entscheidend</td>
                        </tr>
                        <tr>
                            <td><strong>Gef√§√üe</strong></td>
                            <td>25-50%</td>
                            <td>Thromboembolien, Schlaganfall</td>
                            <td>Risiko steigt mit Alter</td>
                        </tr>
                        <tr>
                            <td><strong>Haut/Haare</strong></td>
                            <td>20-30%</td>
                            <td>D√ºnnes Haar, Hypopigmentierung</td>
                            <td>Variable Auspr√§gung</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Neurologische und psychiatrische Manifestationen</h3>
                <div class="highlight-box">
                    <h4>ZNS-Beteiligung bei CBS-Mangel</h4>
                    <p><strong>Kognitive Beeintr√§chtigung:</strong></p>
                    <ul>
                        <li><strong>IQ-Spektrum:</strong> 30-130, Median ~65 (unbehandelt)</li>
                        <li><strong>Lernbehinderung:</strong> 65% der Patienten</li>
                        <li><strong>Aufmerksamkeits-Defizit:</strong> ADHS-√§hnliche Symptome</li>
                        <li><strong>Sprachentwicklung:</strong> Oft verz√∂gert</li>
                    </ul>
                    
                    <p><strong>Neurologische Symptome:</strong></p>
                    <ul>
                        <li><strong>Krampfanf√§lle:</strong> 20-25%, meist generalisiert</li>
                        <li><strong>Bewegungsst√∂rungen:</strong> Dystonie, Tremor</li>
                        <li><strong>Spastik:</strong> Bei schweren Formen</li>
                        <li><strong>Migr√§ne:</strong> H√§ufiger als in Normalbev√∂lkerung</li>
                    </ul>
                    
                    <p><strong>Psychiatrische Auff√§lligkeiten:</strong></p>
                    <ul>
                        <li><strong>Depression:</strong> 30-40% der Erwachsenen</li>
                        <li><strong>Angstst√∂rungen:</strong> Soziale Phobie h√§ufig</li>
                        <li><strong>Pers√∂nlichkeitsst√∂rungen:</strong> Zwanghafte Z√ºge</li>
                        <li><strong>Psychosen:</strong> Selten, meist bei Late-onset</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Vaskul√§re Komplikationen</h3>
                <div class="case-study">
                    <h4>‚ö° Thromboembolische Ereignisse</h4>
                    <p><strong>Arteriell (h√§ufiger):</strong></p>
                    <ul>
                        <li><strong>Zerebrale Isch√§mie:</strong> Schlaganfall bereits im Kindesalter</li>
                        <li><strong>Koronare Herzkrankheit:</strong> Fr√ºhe Atherosklerose</li>
                        <li><strong>Periphere arterielle Verschl√ºsse:</strong> Claudicatio intermittens</li>
                        <li><strong>Retinale Arterienverschl√ºsse:</strong> Visusverlust</li>
                    </ul>
                    
                    <p><strong>Ven√∂s (seltener):</strong></p>
                    <ul>
                        <li><strong>Tiefe Beinvenenthrombose:</strong> Besonders post-operativ</li>
                        <li><strong>Pulmonalembolie:</strong> Lebensbedrohlich</li>
                        <li><strong>Zerebrale Sinusthrombose:</strong> Kopfschmerzen, Krampfanf√§lle</li>
                        <li><strong>Portale Hypertension:</strong> Bei Leberthrombosen</li>
                    </ul>
                    
                    <p><strong>Risikofaktoren f√ºr Thrombosen:</strong></p>
                    <ul>
                        <li><strong>Homocystein-Spiegel >100 Œºmol/l</strong></li>
                        <li><strong>B6-non-responsive Formen</strong></li>
                        <li><strong>Schlechte Therapiecompliance</strong></li>
                        <li><strong>Zus√§tzliche Risikofaktoren:</strong> Rauchen, OAK, Immobilisation</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Remethylierungsdefekte: Unterschiedliche Ph√§notypen</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Defekt</th>
                            <th>Manifestationsalter</th>
                            <th>Hauptsymptome</th>
                            <th>Prognose</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>MTHFR-Mangel</strong></td>
                            <td>S√§uglingsalter</td>
                            <td>Mikrozephalie, Krampfanf√§lle, Apnoen</td>
                            <td>Oft letal, schwere Behinderung</td>
                        </tr>
                        <tr>
                            <td><strong>CblC (fr√ºh)</strong></td>
                            <td>Neonatal</td>
                            <td>Retinopathie, Megaloblast√§re An√§mie</td>
                            <td>Gut bei fr√ºher Therapie</td>
                        </tr>
                        <tr>
                            <td><strong>CblC (sp√§t)</strong></td>
                            <td>Jugend/Erwachsene</td>
                            <td>Psychiatrische Symptome, Myelopathie</td>
                            <td>Variable, oft progressiv</td>
                        </tr>
                        <tr>
                            <td><strong>CblG-Defekt</strong></td>
                            <td>Variable</td>
                            <td>Megaloblast√§re An√§mie, ZNS-Symptome</td>
                            <td>Gut bei ad√§quater B12-Therapie</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>CblC-Defekt: Fr√ºhe vs. sp√§te Form</h3>
                <div class="pathway-diagram">
                    <h4>Altersabh√§ngige Manifestationen</h4>
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
                            <h5 style="color: #dc2626; margin-bottom: 10px;">üë∂ Fr√ºhe Form (0-2 Jahre)</h5>
                            <ul style="font-size: 0.9em; color: #dc2626;">
                                <li><strong>H√§matologisch:</strong> Megaloblast√§re An√§mie</li>
                                <li><strong>Ophthalmologisch:</strong> Bull's eye Makulopathie</li>
                                <li><strong>Renal:</strong> Tubulopathie</li>
                                <li><strong>ZNS:</strong> Entwicklungsr√ºckstand mild</li>
                                <li><strong>Prognose:</strong> Gut bei fr√ºher Therapie</li>
                            </ul>
                        </div>
                        
                        <div style="background: linear-gradient(135deg, #fff7ed, #fed7aa); padding: 15px; border-radius: 8px; border: 2px solid #f97316;">
                            <h5 style="color: #ea580c; margin-bottom: 10px;">üßë Sp√§te Form (>2 Jahre)</h5>
                            <ul style="font-size: 0.9em; color: #ea580c;">
                                <li><strong>Neurologisch:</strong> Myelopathie, Neuropathie</li>
                                <li><strong>Psychiatrisch:</strong> Depression, Psychose</li>
                                <li><strong>Kognition:</strong> Demenz-√§hnliche Symptome</li>
                                <li><strong>H√§matologie:</strong> Oft normal</li>
                                <li><strong>Prognose:</strong> Variable, oft progressiv</li>
                            </ul>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <h4>Bull's Eye Makulopathie bei CblC</h4>
                    <p><strong>Charakteristika:</strong></p>
                    <ul>
                        <li><strong>Aussehen:</strong> Zentrale Atrophie mit erhaltener perimakul√§rer Zone</li>
                        <li><strong>H√§ufigkeit:</strong> 85% der fr√ºhen Form, 20% der sp√§ten Form</li>
                        <li><strong>Progression:</strong> Meist stabil nach Therapiebeginn</li>
                        <li><strong>Funktionell:</strong> Zentrale Skotome, Photophobie</li>
                        <li><strong>Monitoring:</strong> Regelm√§√üige ophthalmologische Kontrollen</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Phenotyp-Genotyp-Korrelationen</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Gen</th>
                            <th>H√§ufige Mutationen</th>
                            <th>Ph√§notyp</th>
                            <th>B6/B12-Response</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>CBS</strong></td>
                            <td>p.I278T (responsive)<br>p.G307S (non-responsive)</td>
                            <td>Klassische Homocystinurie</td>
                            <td>50% B6-responsiv</td>
                        </tr>
                        <tr>
                            <td><strong>MTHFR</strong></td>
                            <td>p.R594Q, p.E204K</td>
                            <td>Schwere fr√ºhe Enzephalopathie</td>
                            <td>Fols√§ure-responsiv</td>
                        </tr>
                        <tr>
                            <td><strong>MMACHC</strong></td>
                            <td>c.271dupA (fr√ºh)<br>c.482G>A (sp√§t)</td>
                            <td>CblC-Defekt</td>
                            <td>OH-Cbl erforderlich</td>
                        </tr>
                        <tr>
                            <td><strong>MTR</strong></td>
                            <td>p.P1173L, p.D919G</td>
                            <td>CblG-Defekt</td>
                            <td>Me-Cbl-responsiv</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('diagnostik')">Weiter zur Diagnostik ‚Üí</button>
            </div>
        </div>

        <!-- Diagnostik -->
        <div class="content-section" id="diagnostik">
            <h2 class="section-title">üî¨ Diagnostik und Management</h2>
            
            <div class="subsection">
                <h3>Diagnostisches Vorgehen</h3>
                <div class="diagnostic-flow">
                    <div class="flow-step">
                        <strong>Klinischer Verdacht</strong><br>
                        Marfanoid, Linsenektopie?<br>
                        Thrombosen? ZNS-Symptome?
                    </div>
                    <div class="flow-arrow"></div>
                    <div class="flow-step">
                        <strong>Basis-Screening</strong><br>
                        Homocystein (n√ºchtern)<br>
                        Methionin, Folat, B12
                    </div>
                    <div class="flow-arrow"></div>
                    <div class="flow-step">
                        <strong>Erweiterte Diagnostik</strong><br>
                        Methylmalons√§ure (Urin)<br>
                        Aminos√§uren-Chromatographie
                    </div>
                    <div class="flow-arrow"></div>
                    <div class="flow-step">
                        <strong>Genetische Best√§tigung</strong><br>
                        Sequenzierung<br>
                        Funktionelle Tests
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Labordiagnostik im Detail</h3>
                <div class="highlight-box">
                    <h4>Homocystein-Bestimmung: Methodische Aspekte</h4>
                    <p><strong>Pr√§analytik (kritisch!):</strong></p>
                    <ul>
                        <li><strong>N√ºchternblutentnahme:</strong> 12h Nahrungskarenz</li>
                        <li><strong>EDTA-Plasma:</strong> Sofortige Zentrifugation bei 4¬∞C</li>
                        <li><strong>Versand:</strong> Tiefgefroren, Trockeneisversand</li>
                        <li><strong>St√∂rfaktoren:</strong> H√§molyse, Methionin-Belastung</li>
                    </ul>
                    
                    <p><strong>Referenzbereiche (altersabh√§ngig):</strong></p>
                    <ul>
                        <li><strong>Neugeborene:</strong> 3-8 Œºmol/l</li>
                        <li><strong>Kinder (1-15 J):</strong> 5-12 Œºmol/l</li>
                        <li><strong>Erwachsene:</strong> 5-15 Œºmol/l</li>
                        <li><strong>Therapieziel:</strong> <30 Œºmol/l (CBS), <15 Œºmol/l (andere)</li>
                    </ul>
                </div>
                
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Analyt</th>
                            <th>Material</th>
                            <th>Methode</th>
                            <th>Besonderheiten</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Homocystein</strong></td>
                            <td>EDTA-Plasma</td>
                            <td>HPLC, LC-MS/MS</td>
                            <td>Reduktion mit TCEP n√∂tig</td>
                        </tr>
                        <tr>
                            <td><strong>Aminos√§uren</strong></td>
                            <td>Plasma/Urin</td>
                            <td>Ionenaustausch-Chromatographie</td>
                            <td>Methionin-Pattern diagnostisch</td>
                        </tr>
                        <tr>
                            <td><strong>Methylmalons√§ure</strong></td>
                            <td>Urin</td>
                            <td>GC-MS, LC-MS/MS</td>
                            <td>Kreatinin-adjustiert</td>
                        </tr>
                        <tr>
                            <td><strong>CBS-Aktivit√§t</strong></td>
                            <td>Kultivierte Fibroblasten</td>
                            <td>Radioaktiver Assay</td>
                            <td>Goldstandard f√ºr CBS-Mangel</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Differentialdiagnostische Algorithmen</h3>
                <div class="pathway-diagram">
                    <h4>Homocystein-erh√∂ht: Systematisches Vorgehen</h4>
                    <div style="background: #f8fafc; padding: 20px; border-radius: 10px; margin: 20px 0;">
                        <div style="text-align: center; margin-bottom: 20px;">
                            <div class="enzyme-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">Homocystein ‚Üë (>20 Œºmol/l)</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 15px; margin: 20px 0;">
                            <div style="text-align: center; padding: 15px; background: #fef2f2; border-radius: 8px; border: 2px solid #fca5a5;">
                                <h5 style="color: #dc2626;">Methionin ‚Üë‚Üë</h5>
                                <p style="color: #dc2626; font-size: 0.9em;">CBS-Mangel</p>
                                <div style="margin: 10px 0;">
                                    <div class="metabolite-box" style="font-size: 0.8em;">B6-Test</div>
                                    <div class="metabolite-box" style="font-size: 0.8em;">CBS-Sequenzierung</div>
                                </div>
                            </div>
                            
                            <div style="text-align: center; padding: 15px; background: #fff7ed; border-radius: 8px; border: 2px solid #fed7aa;">
                                <h5 style="color: #ea580c;">Methionin ‚Üì, MMA ‚Üë</h5>
                                <p style="color: #ea580c; font-size: 0.9em;">CblC/CblF-Defekt</p>
                                <div style="margin: 10px 0;">
                                    <div class="metabolite-box" style="font-size: 0.8em;">MMACHC-Sequenzierung</div>
                                    <div class="metabolite-box" style="font-size: 0.8em;">OH-Cbl-Test</div>
                                </div>
                            </div>
                            
                            <div style="text-align: center; padding: 15px; background: #f0fdf4; border-radius: 8px; border: 2px solid #bbf7d0;">
                                <h5 style="color: #16a34a;">Methionin ‚Üì, MMA normal</h5>
                                <p style="color: #16a34a; font-size: 0.9em;">MTHFR/MTR-Defekt</p>
                                <div style="margin: 10px 0;">
                                    <div class="metabolite-box" style="font-size: 0.8em;">Folat/B12 messen</div>
                                    <div class="metabolite-box" style="font-size: 0.8em;">Gensequenzierung</div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Funktionelle Tests</h3>
                <div class="case-study">
                    <h4>üß™ B6-Responsivit√§ts-Test bei CBS-Mangel</h4>
                    <p><strong>Indikation:</strong> Alle Patienten mit gesichertem CBS-Mangel</p>
                    
                    <p><strong>Protokoll:</strong></p>
                    <ul>
                        <li><strong>Baseline:</strong> Homocystein 3x bestimmen (Mittelwert)</li>
                        <li><strong>Testdosis:</strong> Pyridoxin 100-500 mg/d p.o. f√ºr 6 Wochen</li>
                        <li><strong>Kontrolle:</strong> Homocystein nach 6 Wochen</li>
                        <li><strong>Bewertung:</strong> >20% Reduktion = responsiv</li>
                    </ul>
                    
                    <p><strong>Vorsichtsma√ünahmen:</strong></p>
                    <ul>
                        <li><strong>Maximaldosis:</strong> 500 mg/d (Neuropathie-Risiko)</li>
                        <li><strong>Kontrolle:</strong> Neurologische Untersuchung</li>
                        <li><strong>Begleittherapie:</strong> Keine √Ñnderung w√§hrend Test</li>
                    </ul>
                    
                    <p><strong>Interpretation:</strong></p>
                    <ul>
                        <li><strong>Responder:</strong> Lebenslange B6-Therapie ausreichend</li>
                        <li><strong>Non-Responder:</strong> Komplexe Therapie mit Di√§t + Betain</li>
                        <li><strong>Partial-Responder:</strong> Kombinationstherapie</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Molekulargenetische Diagnostik</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Gen</th>
                            <th>Chromosom</th>
                            <th>Exons</th>
                            <th>H√§ufige Mutationen</th>
                            <th>Besonderheiten</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>CBS</strong></td>
                            <td>21q22.3</td>
                            <td>17</td>
                            <td>p.I278T (28%), p.G307S (12%)</td>
                            <td>B6-Response korreliert mit Mutation</td>
                        </tr>
                        <tr>
                            <td><strong>MTHFR</strong></td>
                            <td>1p36.22</td>
                            <td>11</td>
                            <td>p.R594Q, p.E204K</td>
                            <td>Thermolabilit√§ts-Test m√∂glich</td>
                        </tr>
                        <tr>
                            <td><strong>MMACHC</strong></td>
                            <td>1p34.1</td>
                            <td>4</td>
                            <td>c.271dupA, c.482G>A</td>
                            <td>Mutation korreliert mit Ph√§notyp</td>
                        </tr>
                        <tr>
                            <td><strong>MTR</strong></td>
                            <td>1q43</td>
                            <td>33</td>
                            <td>p.P1173L, p.D919G</td>
                            <td>Gro√üe Genduplikationen m√∂glich</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Neugeborenenscreening</h3>
                <div class="highlight-box">
                    <h4>MS/MS-basiertes Screening</h4>
                    <p><strong>Analyten:</strong></p>
                    <ul>
                        <li><strong>Methionin:</strong> Prim√§rmarker f√ºr CBS-Mangel</li>
                        <li><strong>Methionin/Phenylalanin-Ratio:</strong> Verbesserter Marker</li>
                        <li><strong>Homocystein:</strong> Direktmessung m√∂glich, aber aufwendig</li>
                    </ul>
                    
                    <p><strong>Screening-Performance:</strong></p>
                    <ul>
                        <li><strong>Sensitivit√§t:</strong> 95% f√ºr CBS-Mangel</li>
                        <li><strong>Spezifit√§t:</strong> 99,5% bei optimierten Cut-offs</li>
                        <li><strong>PPV:</strong> Variabel je nach Pr√§valenz (5-20%)</li>
                        <li><strong>Limitation:</strong> B6-responsive Formen oft √ºbersehen</li>
                    </ul>
                    
                    <p><strong>Follow-up bei positivem Screening:</strong></p>
                    <ul>
                        <li><strong>Sofort:</strong> Homocystein + Methionin bestimmen</li>
                        <li><strong>Within 48h:</strong> Vollst√§ndige Aminos√§uren-Analyse</li>
                        <li><strong>Therapiebeginn:</strong> Bei best√§tigtem Befund umgehend</li>
                        <li><strong>Genetik:</strong> Famili√§re Mutationsanalyse</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Therapiestrategien nach Defekttyp</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Defekt</th>
                            <th>Erste Wahl</th>
                            <th>Zusatztherapie</th>
                            <th>Therapieziel</th>
                            <th>Monitoring</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>CBS (B6-resp.)</strong></td>
                            <td>Pyridoxin 100-500 mg/d</td>
                            <td>Fols√§ure 5-10 mg/d</td>
                            <td>Homocystein <50 Œºmol/l</td>
                            <td>Alle 3-6 Monate</td>
                        </tr>
                        <tr>
                            <td><strong>CBS (Non-resp.)</strong></td>
                            <td>Met-Restriktion + Betain</td>
                            <td>Cystin-Substitution</td>
                            <td>Homocystein <100 Œºmol/l</td>
                            <td>Monatlich initial</td>
                        </tr>
                        <tr>
                            <td><strong>MTHFR</strong></td>
                            <td>Folins√§ure 50-100 mg/d</td>
                            <td>Betain 6-9 g/d</td>
                            <td>Homocystein <30 Œºmol/l</td>
                            <td>Alle 1-3 Monate</td>
                        </tr>
                        <tr>
                            <td><strong>CblC/CblG</strong></td>
                            <td>OH-/Me-Cobalamin</td>
                            <td>Betain + Fols√§ure</td>
                            <td>Homocystein <20 Œºmol/l</td>
                            <td>Alle 2-4 Monate</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Di√§tmanagement bei CBS-Mangel</h3>
                <div class="case-study">
                    <h4>üçΩÔ∏è Methionin-restringierte Di√§t</h4>
                    <p><strong>Indikation:</strong> B6-non-responsive CBS-Mangel</p>
                    
                    <p><strong>Di√§tprinzipien:</strong></p>
                    <ul>
                        <li><strong>Methionin-Zufuhr:</strong> 10-15 mg/kg/d (Normal: 45 mg/kg/d)</li>
                        <li><strong>Protein-Restriktion:</strong> 0,8-1,2 g/kg/d (vs. 1,5 g/kg normal)</li>
                        <li><strong>Methionin-freie Aminos√§uren-Mischung:</strong> Zur Protein-Erg√§nzung</li>
                        <li><strong>Cystin-Supplementation:</strong> 100-200 mg/kg/d</li>
                    </ul>
                    
                    <p><strong>Erlaubte/verbotene Lebensmittel:</strong></p>
                    <ul>
                        <li><strong>Sehr eingeschr√§nkt:</strong> Fleisch, Fisch, Eier, Milchprodukte, N√ºsse</li>
                        <li><strong>M√§√üig erlaubt:</strong> Brot, Getreide (spezielle Produkte)</li>
                        <li><strong>Frei:</strong> Obst, Gem√ºse (meiste), Fette, Zucker</li>
                        <li><strong>Spezial-Produkte:</strong> Methionin-arme Mehle, Pasta</li>
                    </ul>
                    
                    <p><strong>Praktische Umsetzung:</strong></p>
                    <ul>
                        <li><strong>Ern√§hrungsberatung:</strong> Spezialisierte Di√§tassistentin erforderlich</li>
                        <li><strong>N√§hrwert-Berechnung:</strong> Software-gest√ºtzte Planung</li>
                        <li><strong>Kontrollen:</strong> Gewicht, L√§ngenwachstum, Albumin</li>
                        <li><strong>Compliance:</strong> Regelm√§√üige Schulungen, Rezeptsammlungen</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Langzeit-Monitoring und Komplikationen</h3>
                <div class="highlight-box">
                    <h4>Strukturiertes Follow-up-Programm</h4>
                    <p><strong>Biochemisch (alle 3-6 Monate):</strong></p>
                    <ul>
                        <li><strong>Homocystein:</strong> Therapie-Monitoring</li>
                        <li><strong>Methionin:</strong> Bei Di√§t-Patienten</li>
                        <li><strong>Vitamin-Status:</strong> B6, B12, Fols√§ure</li>
                        <li><strong>Ern√§hrungsstatus:</strong> Albumin, Prealbumin</li>
                    </ul>
                    
                    <p><strong>Ophthalmologisch (j√§hrlich):</strong></p>
                    <ul>
                        <li><strong>Visus:</strong> Refraktionsbestimmung</li>
                        <li><strong>Spaltlampe:</strong> Linsenposition, Glaukom</li>
                        <li><strong>Funduskopie:</strong> Bei CblC: Makulopathie</li>
                        <li><strong>Gesichtsfeld:</strong> Bei symptomatischen Patienten</li>
                    </ul>
                    
                    <p><strong>Kardiovaskul√§r (altersabh√§ngig):</strong></p>
                    <ul>
                        <li><strong>Blutdruck:</strong> Regelm√§√üige Kontrollen</li>
                        <li><strong>Lipidstatus:</strong> Bei Erwachsenen j√§hrlich</li>
                        <li><strong>Echo/EKG:</strong> Bei kardiovaskul√§ren Risikofaktoren</li>
                        <li><strong>Thrombophilie-Diagnostik:</strong> Bei Thrombose-Anamnese</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <div style="text-align: center; margin-top: 2rem; padding: 2rem; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: var(--border-radius); border: 2px solid var(--info-color);">
                    <h3 style="color: var(--info-color); margin-bottom: 1rem;">üéâ Lerneinheit abgeschlossen!</h3>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;">Sie haben die wichtigsten Aspekte der Homocystinurie erfolgreich durchgearbeitet.</p>
                    <div class="completion-badge">Expertenwissen Homocystinurie zertifiziert</div>
                    <p style="color: var(--text-secondary); margin-top: 1.5